Gynecological cancer highlights from ESMO 2025

32 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Prof. Nicoletta Colombo joins us in Berlin to share her perspectives on the latest endometrial and ovarian cancer data presented at ESMO 2025.

Prof. Colombo reviews data from the following studies:

- ENGOT-ov65/KEYNOTE-B96: Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomised double-blind phase 3 study. Colombo N, et al. Abstract LBA3, ESMO 2025

- AtTEnd/ENGOT-EN7: Final overall survival results from the randomised double-blind phase 3 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. Barrentina Ginesta M.P, et al. Abstract LBA39, ESMO 2025

- REJOICE-Ovarian01: Raludotatug deruxtecan in patients with platinum-resistant ovarian cancer: primary analysis of the phase 2 dose-optimisation part of REJOICE-Ovarian01. Ray-Coquard I.L, et al. Abstract LAB42, ESMO 2025


How will these data impact clinical practice? Watch to find out!


See more updates from ESMO 2025 on our website: https://cor2ed.com/n-connect/programmes/highlights-from-esmo-2025/?media=4


Looking for similar gynecological cancer programmes?

Update From ASCO 2025: https://cor2ed.com/n-connect/programmes/highlights-asco-2025/?media=3

HER2 testing: The evolving role of immunohistochemistry (IHC): https://cor2ed.com/precision-oncology-connect/programmes/her2-testing-role-of-ihc/?media=1



Follow OBSTETRICS & GYNECOLOGY CONNECT on:

X – https://x.com/OBGynConnect

LinkedIn – https://www.linkedin.com/company/ob-gyn-connect/



This video was developed by cor2ed.com

Published October 2025



Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Categoria
Oncology
Commenta per primo questo video.

Prossimo